| Abstrakt: |
A recent study conducted by researchers at Philipps-University in Marburg, Germany, explored the use of personalized medicine in breast and gynecological cancers. The study analyzed patient characteristics, next-generation sequencing (NGS) results, treatment recommendations, therapy received, and clinical outcomes. The findings showed that patients who underwent molecular-matched treatment (MMT) based on NGS-guided precision oncology had significantly prolonged progression-free survival compared to those who did not receive MMT. The study concluded that NGS-guided precision oncology can lead to improved clinical outcomes in a subgroup of patients with breast and gynecological cancers. [Extracted from the article] |
